C7CAR5

C7CAR5 is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD5-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphoma (PTCL). It is characterized by the use of a low-affinity CD5 binder, which was specifically selected to mitigate the risk of fratricide—a process where CAR-T cells target and destroy each other due to the endogenous expression of CD5 on T cells. Compared to high-affinity constructs like A2CAR5, C7CAR5 demonstrates a reduced tendency for fratricide and excessive cytokine release while maintaining potent cytotoxic activity against malignant cells. Research into C7CAR5 also involves the integration of CRISPR/Cas9 gene editing to knock out CD5 and the T-cell receptor alpha constant (TRAC) locus, aiming to create a fratricide-resistant, allogeneic 'off-the-shelf' therapeutic platform with improved persistence and reduced exhaustion.

Other names

anti-CD5 CAR-T (low affinity)